Antares Therapeutics key facts
as of Oct 2026- Operator of a biotechnology company intended to develop first-in-class precision medicines targeting previously undruggable cancer and serious disease targets.
- Antares Therapeutics is valued at approximately $299.0M as of Oct 2026, per PrivateMarketView’s mark.
- It has raised $177.0M across 2 recorded rounds; the latest was Early Stage VC ($30.0M) in May 2025.
- Notable investors include Lightspeed Venture Partners, Cormorant Asset Management, Invus Opportunities, Omega Funds, Atlas Venture — 11 tracked in total.
- 1 institutional filer reports fund marks on Antares Therapeutics across 5 filings.
- Antares Therapeutics has filed 2 Form Ds with the SEC, most recently May 2025 ($30.0M sold to 35 investors).
- Status: Privately Held (backing).
Fund marks imply 5.1× the round — treated as a units change, held — shown at its early-stage round, Apr 2025 ($299.0M post-money).
- ·The complete investor list: 11 names
- ·Watch Antares Therapeutics: the Monday email on marks, rounds and moves
Institutional fund marks on Antares Therapeutics
1 filers · latest May 20261 SEC-registered fund reported 5 fair-value marks on Antares Therapeutics between May 2025 and May 2026. Filer-level marks and implied $/share are available to Pro members.
Membership and data by Private Market View
Antares Therapeutics funding rounds
2 roundsWho backs Antares Therapeutics
11+Antares Therapeutics valuation
Antares Therapeutics is valued at approximately $299 million as of Oct 2026. The figure is set by institutional fund marks. The reference point is its early-stage round in Apr 2025, at a $299 million post-money valuation.
How much has Antares Therapeutics raised?
Antares Therapeutics has raised $177 million in total; 2 of its rounds are on record. The largest on record was a $40 million early-stage round in Mar 2025; the most recent was a $30 million early-stage round in May 2025.
Antares Therapeutics has filed 2 Form Ds with the SEC, most recently in May 2025 ($30 million sold to 35 investors).
Institutional holders and vehicles
1 SEC-registered fund reported 5 fair-value marks on Antares Therapeutics between May 2025 and May 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.
Antares Therapeutics investors
11 investors are on record for Antares Therapeutics, including Lightspeed Venture Partners, Cormorant Asset Management, Invus Opportunities and Omega Funds. By type, the record holds 3 venture capital firms, 1 family office and 1 private equity firm. The early-stage round in May 2025 drew 35 investors.
About Antares Therapeutics
Operator of a biotechnology company intended to develop first-in-class precision medicines targeting previously undruggable cancer and serious disease targets. The company offers an integrated drug discovery platform combining advanced computational chemistry, predictive sciences and experimental biology, enabling the development of transformative therapies for patients with high unmet medical needs.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2025
- Employees
- 100
- Website
- antaresrx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.